ProfileGDS5678 / 1421538_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 32% 32% 32% 32% 31% 31% 32% 37% 32% 32% 32% 32% 32% 32% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.7615632
GSM967853U87-EV human glioblastoma xenograft - Control 22.7360832
GSM967854U87-EV human glioblastoma xenograft - Control 32.7364232
GSM967855U87-EV human glioblastoma xenograft - Control 42.6787232
GSM967856U87-EV human glioblastoma xenograft - Control 52.6640431
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.791131
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.7775732
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.8439737
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.7002632
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.7130432
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.7227532
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.6857932
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.7314432
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.7259732